In 2018 we reported on a number of developments in life sciences
IP and regulatory law. Our most-read articles were:
#1 a June
update on biosimilars (authored by Urszula Wojtyra);
#2 a "live"
summary chart of Vanessa's Law developments (authored
by Katie Lee); and #3 an
article reporting on a decision that a use patent for
infliximab was valid and infringed by
Hospira's biosimilar INFLECTRA (authored
by Katie Lee and Urszula Wojtyra). We review these and other
top developments below.
Decisions under appeal are noted with an *.
1. Biosimilars Update: Consultation on naming approaches;
Janssen patent valid and infringed by INFLECTRA; CADTH
environmental scans
Our most-read article this year was our mid-year update on biosimilars, including on 2018
biosimilar marketing approvals (there were four by year-end, with a
December approval of BGP Pharma's FULPHILA
(pegfilgrastim), a biosimilar of
NEULASTA) and ongoing litigation matters. There
was a
consultatio
